<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01120639</url>
  </required_header>
  <id_info>
    <org_study_id>BRN0012</org_study_id>
    <secondary_id>SU-04202010-5726</secondary_id>
    <secondary_id>17774</secondary_id>
    <nct_id>NCT01120639</nct_id>
  </id_info>
  <brief_title>PI/II of Temozolomide &amp; Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform</brief_title>
  <official_title>A Phase I/II Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and effectiveness of a combination
      treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved
      chemotherapy drug temozolomide
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of hypofractionated radiotherapy given in 5 fractions with temozolomide for the treatment of glioblastoma multiforme</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the progression-free survival rate.</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the short- and long-term adverse effects.</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the radiographic response rate.</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the overall survival rate.</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform patterns of failure analysis.</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess quality of life during treatment.</measure>
    <time_frame>Duration of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Cancer of Brain and Nervous System</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>PTV (Planning Target Volume) less than 60 cm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated radiotherapy with concurrent temozolomide
Dose Levels:
25 Gy in 5 fractions
30 Gy in 5 fractions
35 Gy in 5 fractions
40 Gy in 5 fractio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTV (Planning Target Volume) between 60 and 150 cm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated radiotherapy with concurrent temozolomide
Dose Levels:
25 Gy in 5 fractions
30 Gy in 5 fractions
35 Gy in 5 fractions
40 Gy in 5 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>75 mg/m2/day, oral</description>
    <arm_group_label>PTV (Planning Target Volume) less than 60 cm3</arm_group_label>
    <arm_group_label>PTV (Planning Target Volume) between 60 and 150 cm3</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>PTV (Planning Target Volume) less than 60 cm3</arm_group_label>
    <arm_group_label>PTV (Planning Target Volume) between 60 and 150 cm3</arm_group_label>
    <other_name>Cyberknife surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed newly diagnosed glioblastoma multiforme.  Diagnosis
             must be made by surgical biopsy or excision

          -  The tumor must be supratentorial in location

          -  The planning target volume (tumor plus margin) must measure &lt;= 150 cm^3 in volume

          -  Age &gt;=18 years

          -  Life expectancy of at least 12 weeks

          -  Patient must have adequate organ function to tolerate temozolomide (details in the
             protocol)

        Exclusion Criteria:

          -  Patients who have previously been treated with brain irradiation to the region that
             would result in overlap of the radiation fields

          -  Tumor foci detected below the tentorium

          -  Multifocal disease or leptomeningeal spread

          -  Prior allergic reaction to the study drugs involved in this protocol

          -  Patients with pacemaker will be allowed to undergo CT instead of MRI

          -  Pediatric patients (age &lt;18), pregnant women, and nursing patients will be excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Soltys</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Modlin</last_name>
    <phone>(650) 723-8843</phone>
    <email>lmodlin@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Chung</last_name>
      <phone>650-736-0798</phone>
      <email>mxchung@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Clinical Trials Office</last_name>
      <phone>(650) 498-7061</phone>
    </contact_backup>
    <investigator>
      <last_name>Scott Soltys</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Lawrence Recht</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Griffith R. Harsh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Catrice Gibbs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara Choi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Daniel Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
